Ralph G. Zinner

Aung Naing7
Jennifer J. Wheler6
Siqing Fu6
7Aung Naing
6Jennifer J. Wheler
6Siqing Fu
Learn More
The standard treatment for most advanced cancers is multidrug therapy. Unfortunately, combinations in the clinic often do not perform as predicted. Therefore, to complement identifying rational drug combinations based on biological assumptions, we hypothesized that a functional screen of drug combinations, without limits on combination sizes, will aid the(More)
  • Chad Tang, Denis L. Fontes Jardim, Gerald S. Falchook, Kenneth Hess, Siqing Fu, Jennifer J. Wheler +8 others
  • 2014
PURPOSE MET alterations including amplifications and nucleotide variations have been associated with resistance to therapy and aggressive clinical behavior. EXPERIMENTAL DESIGN The medical records of patients presenting to the University of Texas MD Anderson Cancer Center Phase I Clinic with relapsed or metastatic ovarian cancers and known MET nucleotide(More)
  • Filip Janku, Philipp Angenendt, Apostolia M. Tsimberidou, Siqing Fu, Aung Naing, Gerald S. Falchook +15 others
  • 2015
Cell-free (cf) DNA in the plasma of cancer patients offers an easily obtainable source of biologic material for mutation analysis. Plasma samples from 157 patients with advanced cancers who progressed on systemic therapy were tested for 21 mutations in BRAF, EGFR, KRAS, and PIK3CA using the BEAMing method and results were compared to mutation analysis of(More)
BACKGROUND TAS-106 was designed to inhibit RNA synthesis by blocking RNA polymerases I, II, and III. METHODS This was a single-center, open-label, phase I study to identify the maximum tolerated dose (MTD), pharmacokinetics, and biologic effects of the combination of TAS-106 and carboplatin, following a standard 3 + 3 design. This phase I trial was(More)
  • Xiaochun Liu, Susan Kambrick, Siqing Fu, Aung Naing, Vivek Subbiah, George R. Blumenschein +8 others
  • 2016
BACKGROUND Bevacizumab and temsirolimus are active agents in advanced solid tumors. Temsirolimus inhibits mTOR in the PI3 kinase/AKT/mTOR pathway as well as CYP2A, which may be a resistance mechanism for cetuximab. In addition, temsirolimus attenuates upregulation of HIF-1α levels, which may be a resistance mechanism for bevacizumab. PATIENTS AND METHODS(More)
  • Filip Janku, Bart Claes, Helen J. Huang, Gerald S. Falchook, Benoit Devogelaere, Mark Kockx +21 others
  • 2015
Fast and accurate diagnostic systems are needed for further implementation of precision therapy of BRAF-mutant and other cancers. The novel IdyllaTMBRAF Mutation Test has high sensitivity and shorter turnaround times compared to other methods. We used Idylla to detect BRAF V600 mutations in archived formalin-fixed paraffin-embedded (FFPE) tumor samples and(More)
  • Aung Naing, Pete Anderson, Sergei Guma, Hsuan-Chu Chien, Lacey MM McQuinn, Joshua P Hein +3 others
  • 2013
To circumvent significant toxicities associated with high dose systemic IL-2 treatment, organ-specific delivery such as inhalational IL-2 has been studied. Our pre-clinical data demonstrated therapeutic efficacy of aerosol IL-2 in a human OS mouse model with no toxicity. The number of OS lung metastases in the aerosol IL-2 treated group was significantly(More)
  • 1